Intra-Cellular Therapies Announces The Successful Completion Of A Phase Ib/II Study Of ITI-007 In Patients With Schizophrenia

Intra-Cellular Therapies, Inc. announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia...

Read the original post at Psychology / Psychiatry News From Medical News Today ...

Share your thoughts.